The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Global phase 2 data in TNBC look similar to earlier results in China.
The company might have blown Enliven out of the water.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
